This article is more than 5 years old. Information may no longer be current.

VIDEO: Expert highlights research in GI cancer at ASCO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — HemOnc Today Next Gen Innovator Michael S. Lee, MD, assistant professor of medicine at the University of North Carolina, Chapel Hill, and oncologist at the Lineberger Comprehensive Cancer Center, discusses two “key” abstracts in gastrointestinal cancer that were presented at the ASCO Annual Meeting.

The first study Lee reviews is a pooled analysis of four randomized trials that compared the outcomes of patients with high-risk, stage 2 colorectal cancer who received 3 vs. 6 months of adjuvant oxaliplatin-based chemotherapy. The second study he discusses is the phase 3 KEYNOTE-240 study, which compared pembrolizumab (Keytruda, Merck) with best supportive care for second-line therapy in patients with advanced hepatocellular carcinoma.

References:

Finn RS, et al. Abstract 4004. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Iveson T, et al. Abstract 3501. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Lee reports no relevant financial disclosures.